Towards Healthcare
Rapid Genomic Diagnostics 2025 Trends: Next-Gen Sequencing and Long-Read Tech ...

Rapid Genomic Diagnostics Market 2025 Expands as Rare Diseases and Oncology Drive Demand

The rapid genomic diagnostics market is rising due to the growing focus on rare disease & genetic disease diagnostics. North America’s dominance is attributed to technological advancements in bioinformatics.

Content

  • Insight Code: 5822
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

Rapid genomic diagnostics market sees strong growth from 2025–2034, driven by innovation and increasing global demand.

North America is currently leading the rapid genomic diagnostics market due to rising cases of infectious diseases, the development of multi-omics technology, and the development of advanced diagnostics kits.

The rapid genomic diagnostics market includes six segments such as by test type, by application, by technology, by sample type, by end-user, and by region.

Some key players include Illumina, Inc., Oxford Nanopore Technologies, GeneDx (a Sema4 Company), Guardant Health, Baylor Genetics, etc.

Key trends include the rising integration of AI and ML in genomics and the rising cases of infectious diseases.

DNA sequencing enables clinicians to identify genetic diseases, improve disease management, provide personalized reproductive guidance, and develop more effective medicines. Gene sequencing panels are used to identify many potential genetic causes of a suspected disease.

One error per 10,000 base pairs for the whole contiguous sequence is the current global accuracy standard, sometimes referred to as the Bermuda Standards.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions